Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.57 |
| ▸ | TNKS | O95271 | 1/20 | 0.57 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.57 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.56 |
| ▸ | TTR | P02766 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1511647 | 1.00 | NPSR1 (0.59) | NPSR1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29186330 | 0.98 | NPSR1 (0.57) | NPSR1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30904792 | 0.98 | NPSR1 (0.57) | NPSR1HDAC3HDAC4HDAC1HDAC7 | |
| Ethane SCHEMBL3344169 | 0.97 | NPSR1 (0.56) | NPSR1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL15985448 | 0.84 | GLA (0.56) | NPSR1ENPP2TTRAPPGLA | |
| SCHEMBL9214256 | 0.82 | ENPP2 (0.69) | ENPP2TTRKDM4EALDH1A1CA4 | |
| SCHEMBL9214261 | 0.82 | ENPP2 (0.69) | ENPP2TTRKDM4EALDH1A1CA4 | |
| SCHEMBL69146 | 0.82 | NPSR1 (0.74) | NPSR1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL271386 | 0.82 | NPSR1 (0.74) | NPSR1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL24598773 | 0.81 | ENPP2 (0.62) | ENPP2TTRKDM4EALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883503-B2 | Hydrogel scaffolds for tissue engineering | INDIAN INSTITUTE OF TECHNOLOGY KANPUR (IN) | 2014-11-11 | — | — | US | claimed |
| US-20130236971-A1 | HYDROGEL SCAFFOLDS FOR TISSUE ENGINEERING | INDIAN INSTITUTE OF TECHNOLOGY KANPUR (IN) | 2013-09-12 | — | — | US | claimed |
| WO-2012176023-A1 | HYDROGEL SCAFFOLDS FOR TISSUE ENGINEERING | INDIAN INSTITUTE OF TECHNOLOGY KANPUR (IN) | 2012-12-27 | — | — | WO | claimed |
| US-20240000950-A1 | THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2024-01-04 | — | — | US | disclosed |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | CORNELL UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| EP-4192504-A2 | THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM | Cornell University (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-4192824-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | Cornell University (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-4192825-A2 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | Cornell University (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022031777-A2 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2022-02-10 | — | — | WO | disclosed |
| US-7176214-B2 | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060217412-A1 | Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | PITTS WILLIAM J | 2006-09-28 | — | — | US | disclosed |
| EP-1667955-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF THE ESTROGEN RECEPTOR | SmithKline Beecham Corporation (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005012220-A9 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORP (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20050101626-A1 | Imidazo-fused oxazolo[4,5-beta]pyridine and imidazo-fused thiazolo[4,5-beta]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-12 | — | — | US | disclosed |
| WO-2005012220-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2004106293-A2 | OXAZOLYL - AND THIAZOLYL - PURINE BASED TRICYCLIC COMPOUNDS. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004056798-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000950-A1 | THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM | BET1, BRD4, BAZ2A | NPSR1 3902/4885HDAC3 172/4885HDAC4 209/4885 |
| US-20050101626-A1 | Imidazo-fused oxazolo[4,5-beta]pyridine and imidazo-fused thiazolo[4,5-beta]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | TPMT, IRAK4, P2RX7 | NPSR1 2825/4885HDAC3 255/4885HDAC4 411/4885 |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | XIAP, CUL4A, CUL1 | NPSR1 4159/4885HDAC3 1495/4885HDAC4 2017/4885 |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | BET1, BRD4, PHKB | NPSR1 4166/4885HDAC3 275/4885HDAC4 403/4885 |
| US-20060217412-A1 | Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | TPMT, IRAK4, P2RX7 | NPSR1 2777/4885HDAC3 222/4885HDAC4 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.